BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 29
• 30
• 31

• Pharm Country

  Octagon Research Solutions, Inc. Named Emerging Life Sciences Company of the Year

  May 7, 2012

   · 

  1 min read
• Drug Development

  NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine

  May 7, 2012

   · 

  1 min read
• Drug Development

  Promedior Announces Presentation of Preclinical Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage

  May 7, 2012

   · 

  1 min read
• Pharm Country

  10th Anniversary Multiple Myeloma Research Foundation (MMRF) Laugh for Life: New York Raises Critical Funds for Blood Cancer Research

  May 7, 2012

   · 

  1 min read
• Agilent Technologies Inc. Introduces Preclinical MRI System

  May 7, 2012

   · 

  1 min read
• Biotech Bay

  Fluidigm Corporation Announces Unrestricted Sales into Prenatal Health and Non-Invasive Prenatal Diagnostics Fields of Research

  May 7, 2012

   · 

  1 min read
• Business

  Advanced Cell Technology to Host Conference Call to Discuss 2012 First Quarter Results and Provide Corporate Update on Wednesday, May 9th

  May 7, 2012

   · 

  1 min read
• BioCapital

  Activesite Pharmaceuticals’ Announces the Award of a Competitively Renewed Phase II SBIR Grant From the National Institutes of Health (NIH)

  May 7, 2012

   · 

  1 min read
• Drug Development

  CytRx Corporation Announces Presentation of Complete Clinical Data from INNO-206 Phase 1b/2 Trial at American Society of Clinical Oncology

  May 7, 2012

   · 

  1 min read
• Drug Development

  Galleon Pharmaceuticals, Inc. Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression

  May 7, 2012

   · 

  1 min read